SCM
CCCC icon

Silverarc Capital Management’s C4 Therapeutics CCCC Stock Holding History

Silverarc Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-150,000
Closed -$855K – 71
2024
Q3 		$855K Hold
150,000
– – 0.19% 57
2024
Q2 		$693K Hold
150,000
– – 0.16% 63
2024
Q1 		$1.23M Buy
+150,000
New +$1.16M 0.34% 58

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Silverarc Capital Management's CCCC Position: Q2 2026 in Review

Silverarc Capital Management increased its C4 Therapeutics (CCCC) stake by 59% in Q2 2026, buying an estimated $3.83M and bringing the position to 3,032,060 shares worth $14.2M. The position accounts for 1.47% of the portfolio, ranked #23.

Silverarc Capital Management first reported a position in CCCC in Q1 2024 and has held it in 9 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Silverarc Capital Management held 3,032,060 shares of C4 Therapeutics worth $14.2M as of Q2 2026.
  • Silverarc Capital Management bought 1,120,275 C4 Therapeutics shares in Q2 2026, an estimated $3.83M.
  • C4 Therapeutics made up 1.47% of Silverarc Capital Management's portfolio in Q2 2026, its #23 holding.
  • Silverarc Capital Management first reported a position in C4 Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.